This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davicioni, E. Articles by Anderson, M. J. Search for Related Content PubMed PubMed Citation Articles by Davicioni, E. Articles by Anderson, M. J.

Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas

Departments of ¹ Pathology and ² Preventive Medicine, ³ Keck School of Medicine, and ⁴ Norris Comprehensive Cancer Center, University of Southern California; ⁵ Department of Pathology and Laboratory Medicine, Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California

Requests for reprints: Michael J. Anderson, Department of Pathology and Laboratory Medicine, Saban Research Institute, Children's Hospital Los Angeles, 4650 Sunset Boulevard, MS 103, Los Angeles, CA 90027. Phone: 323-669-5624; Fax: 323-906-8081; E-mail: manderson{at}chla.usc.edu.

Alveolar rhabdomyosarcomas (ARMS) are aggressive soft-tissue sarcomas affecting children and young adults. Most ARMS tumors express the PAX3-FKHR or PAX7-FKHR (PAX-FKHR) fusion genes resulting from the t(2;13) or t(1;13) chromosomal translocations, respectively. However, up to 25% of ARMS tumors are fusion negative, making it unclear whether ARMS represent a single disease or multiple clinical and biological entities with a common phenotype. To test to what extent PAX-FKHR determine class and behavior of ARMS, we used oligonucleotide microarray expression profiling on 139 primary rhabdomyosarcoma tumors and an in vitro model. We found that ARMS tumors expressing either PAX-FKHR gene share a common expression profile distinct from fusion-negative ARMS and from the other rhabdomyosarcoma variants. We also observed that PAX-FKHR expression above a minimum level is necessary for the detection of this expression profile. Using an ectopic PAX3-FKHR and PAX7-FKHR expression model, we identified an expression signature regulated by PAX-FKHR that is specific to PAX-FKHR-positive ARMS tumors. Data mining for functional annotations of signature genes suggested a role for PAX-FKHR in regulating ARMS proliferation and differentiation. Cox regression modeling identified a subset of genes within the PAX-FKHR expression signature that segregated ARMS patients into three risk groups with 5-year overall survival estimates of 7%, 48%, and 93%. These prognostic classes were independent of conventional clinical risk factors. Our results show that PAX-FKHR dictate a specific expression signature that helps define the molecular phenotype of PAX-FKHR-positive ARMS tumors and, because it is linked with disease outcome in ARMS patients, determine tumor behavior. (Cancer Res 2006; 66(14): 6936-46)

This article has been cited by other articles:

				K. Nishijo, Q.-R. Chen, L. Zhang, A. T. McCleish, A. Rodriguez, M. J. Cho, S. I. Prajapati, J. A.L. Gelfond, G. B. Chisholm, J. E. Michalek, et al. Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma Cancer Res., April 1, 2009; 69(7): 2902 - 2911. [Abstract] [Full Text] [PDF]

				T. A. Guise, R. O'Keefe, R. L. Randall, and R. M. Terek Molecular Biology and Therapeutics in Musculoskeletal Oncology J. Bone Joint Surg. Am., March 1, 2009; 91(3): 724 - 732. [Full Text] [PDF]

				K. T. Montone, F. G. Barr, P. J. Zhang, M. D. Feldman, and V. A. LiVolsi Embryonal and Alveolar Rhabdomyosarcoma of Parameningeal Sites in Adults: A Report of 13 Cases International Journal of Surgical Pathology, February 1, 2009; 17(1): 22 - 30. [Abstract] [PDF]

				E. Davicioni, M. J. Anderson, F. G. Finckenstein, J. C. Lynch, S. J. Qualman, H. Shimada, D. E. Schofield, J. D. Buckley, W. H. Meyer, P. H.B. Sorensen, et al. Molecular Classification of Rhabdomyosarcoma--Genotypic and Phenotypic Determinants of Diagnosis: A Report from the Children's Oncology Group Am. J. Pathol., February 1, 2009; 174(2): 550 - 564. [Abstract] [Full Text] [PDF]

				Y.-X. Ren, F. G. Finckenstein, D. A. Abdueva, V. Shahbazian, B. Chung, K. I. Weinberg, T. J. Triche, H. Shimada, and M. J. Anderson Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations Cancer Res., August 15, 2008; 68(16): 6587 - 6597. [Abstract] [Full Text] [PDF]

				F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]

				O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]

				F. G. Barr and R. B. Womer Molecular Diagnosis of Ewing Family Tumors: Too Many Fusions... ? J. Mol. Diagn., September 1, 2007; 9(4): 437 - 440. [Abstract] [Full Text] [PDF]

				L.-W. Chang, B. R. Fontaine, G. D. Stormo, and R. Nagarajan PAP: a comprehensive workbench for mammalian transcriptional regulatory sequence analysis Nucleic Acids Res., July 13, 2007; 35(suppl_2): W238 - W244. [Abstract] [Full Text] [PDF]

				H. C. Olguin, Z. Yang, S. J. Tapscott, and B. B. Olwin Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination J. Cell Biol., June 21, 2007; 177(5): 769 - 779. [Abstract] [Full Text] [PDF]